Upload
PPT-Figure 2 Figure 2. SARS-CoV-2 S antibody seroprevalence, titers, and vaccine doses of

PPT-Figure 2 Figure 2. SARS-CoV-2 S antibody seroprevalence, titers, and vaccine doses of

Author : abigail | Published Date : 2024-09-06

Nilles EJ de St Aubin M Dumas D Duke W Etienne M Abdalla G et al Monitoring Temporal Changes in SARSCoV2 Spike Antibody Levels and VariantSpecific Risk for Infection

amp age years smoothed age amp smoothed years antibody gray dots line participants study ages shading loess percentage dot

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Figure 2 Figure 2. SARS-CoV-2 S antibody..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Figure 2 Figure 2. SARS-CoV-2 S antibody seroprevalence, titers, and vaccine doses of: Transcript

Nilles EJ de St Aubin M Dumas D Duke W Etienne M Abdalla G et al Monitoring Temporal Changes in SARSCoV2 Spike Antibody Levels and VariantSpecific Risk for Infection Dominican Republic March 2021August 2022 Emerg Infect Dis 2023294723733 httpsdoiorg103201eid2904221628. Ia. Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS administered alone and with MVA CS. Eoghan. F. de Barra. 1. , Susanne H. Sheehy. 2. , Katie J. Ewer. 2. - CoV - 2 Patricia Slev, PhD, D(ABCC) Section Chief, Immunology, ARUP Laboratories Associate Professor, University of Utah School of Medicine patricia.slev@aruplab.com 1 DISCLOSURES P Slev None OBJEC Harvala H, McIntyre CL, Imai N, Clasper L, Djoko CF, LeBreton M, et al. High Seroprevalence of Enterovirus Infections in Apes and Old World Monkeys. Emerg Infect Dis. 2012;18(2):283-286. https://doi.org/10.3201/eid1802.111363. Cassar O, Afonso PV, Bassot S, Plancoulaine S, Duprez R, Capuano C, et al. Novel Human Herpesvirus 8 Subtype D Strains in Vanuatu, Melanesia. Emerg Infect Dis. 2007;13(11):1745-1748. https://doi.org/10.3201/eid1311.070636. Minetti A, Kagoli M, Katsulukuta A, Huerga H, Featherstone A, Chiotcha H, et al. Lessons and Challenges for Measles Control from Unexpected Large Outbreak, Malawi. Emerg Infect Dis. 2013;19(2):202-209. https://doi.org/10.3201/eid1902.120301. Sohn YM. Japanese Encephalitis Immunization in South Korea: Past, Present, and Future. Emerg Infect Dis. 2000;6(1):17-24. https://doi.org/10.3201/eid0601.000103. Durand B, Zanella G, Biteau-Coroller F, Locatelli C, Baurier F, Simon C, et al. Anatomy of Bluetongue virus Serotype 8 Epizootic Wave, France, 2007-2008. Emerg Infect Dis. 2010;16(12):1861-1868. https://doi.org/10.3201/eid1612.100412. Guo L, Zhang X, Ren L, Yu X, Chen L, Zhou H, et al. Human Antibody Responses to Avian Influenza A(H7N9) Virus, 2013. Emerg Infect Dis. 2014;20(2):192-200. https://doi.org/10.3201/eid2002.131094. de Vries RD, De Gruyter H, Bestebroer TM, Pronk M, Fouchier R, Osterhaus A, et al. Induction of Influenza (H5N8) Antibodies by Modified Vaccinia Virus Ankara H5N1 Vaccine. Emerg Infect Dis. 2015;21(6):1086-1088. https://doi.org/10.3201/eid2106.150021. Temperton NJ, Chan PK, Simmons G, Zambon MC, Tedder RS, Takeuchi Y, et al. Longitudinally Profiling Neutralizing Antibody Response to SARS Coronavirus with Pseudotypes. Emerg Infect Dis. 2005;11(3):411-416. https://doi.org/10.3201/eid1103.040906. .. Blue line = cut-off; ODr - Optical Density ratio.. Serological titer (farm). Serological titer (sows). Serological titer (finishers). Figure S2.. Distribution of serological titers for . Toxoplasma gondii. Chiu RW, Chim SS, Tong Y, Fung KS, Chan P, Zhao G, et al. Tracing SARS-Coronavirus Variant with Large Genomic Deletion. Emerg Infect Dis. 2005;11(1):168-170. https://doi.org/10.3201/eid1101.040544. Hussain AI, Shanmugam V, Switzer WM, Tsang SX, Fadly A, Thea D, et al. Lack of Evidence of Endogenous Avian Leukosis Virus and Endogenous Avian Retrovirus Transmission to Measles Mumps Rubella Vaccine Recipients. Emerg Infect Dis. 2001;7(1):66-72. https://doi.org/10.3201/eid0701.700066. Kratzel A, Todt D, V’kovski P, Steiner S, Gultom M, Thao T, et al. Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 by WHO-Recommended Hand Rub Formulations and Alcohols. Emerg Infect Dis. 2020;26(7):1592-1595. https://doi.org/10.3201/eid2607.200915.

Download Document

Here is the link to download the presentation.
"Figure 2 Figure 2. SARS-CoV-2 S antibody seroprevalence, titers, and vaccine doses of"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.

Related Documents

Laboratory Serology for SARS

Laboratory Serology for SARS
Figure Figure. Seroprevalence of neutralizing antibody (titers >16) to

Figure Figure. Seroprevalence of neutralizing antibody (titers >16) to
Figure 1 Figure 1. A) Age-dependent herpesvirus 8 (HHV-8) seroprevalence rates

Figure 1 Figure 1. A) Age-dependent herpesvirus 8 (HHV-8) seroprevalence rates
Figure 3 Figure 3. . Age distribution of children with measles reported in Malawi, 2010.

Figure 3 Figure 3. . Age distribution of children with measles reported in Malawi, 2010.
Figure 4 Figure 4. A. Plaque-reduction neutralizing antibody titers (PRNT) according

Figure 4 Figure 4. A. Plaque-reduction neutralizing antibody titers (PRNT) according
Figure 2 Figure 2. Results from a serologic study of the 2007 epizootic wave

Figure 2 Figure 2. Results from a serologic study of the 2007 epizootic wave
Figure 1 Figure 1. Serum antibodies (Abs) in patients infected with influenza A(H7N9)

Figure 1 Figure 1. Serum antibodies (Abs) in patients infected with influenza A(H7N9)
Figure Figure. Results of hemagglutination-inhibition (HI) testing of modified vaccinia

Figure Figure. Results of hemagglutination-inhibition (HI) testing of modified vaccinia
Figure 2 Figure 2. . Correlation of neutralizing antibody titers measured by plaque reduction

Figure 2 Figure 2. . Correlation of neutralizing antibody titers measured by plaque reduction
Figure S1. Distribution of SERASCA® test titers per farm (n=65 farms, finishers)

Figure S1. Distribution of SERASCA® test titers per farm (n=65 farms, finishers)
Figure Figure. Schematic illustration of the epidemiologic relationships between

Figure Figure. Schematic illustration of the epidemiologic relationships between
Figure 1 Figure 1. Western blot antibody reactivity of chicken sera to endogenous

Figure 1 Figure 1. Western blot antibody reactivity of chicken sera to endogenous
Figure 2 Figure 2. Effect of commercially available alcohols in inactivating SARS-CoV-2.

Figure 2 Figure 2. Effect of commercially available alcohols in inactivating SARS-CoV-2.